Dr Barbara Eichhorst at ASH 2014: Final analysis of the international phase III CLL10 study - 101271

Spotlight
Video

Dr Barbara Eichhorst at ASH 2014: Final analysis of the international phase III CLL10 study

EMJ has 458 videos Subscribe Here

Loading........
Description: At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Barbara Eichhorst (University Hospital, Cologne, Germany) discusses the final analysis of the international, randomised, phase III CLL10 study.

Frontline chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab (FCR) has superior efficacy (higher complete response rates, more minimal residual disease [MRD] negativity, longer progression-free survival) versus bendamustine and rituximab in previously untreated and physically fit patients with advanced chronic lymphocytic leukaemia.
Shared By : EMJ
Posted on : 01/09/15
Added : 3 years ago



Recommended

Nothing found.

More From EMJ

Nothing found.